CClinicalTrials.gg
CompletedNCT05506813Updated Nov 9, 2022

Comparative Effects of Cognitive and Motor Dual Task Training on Balance and Quality Of Life in Parkinson's Patients

An interventional study of cognitive training and conventional training and motor dual task training along with conventional therapy in Parkinson Disease, Balance; Distorted and Postural; Defect, sponsored by Riphah International University. Completed at 1 site in Pakistan. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-09.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2022, registered Aug 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

To Compare Effects of Cognitive and Motor Dual Task Training on Balance and Quality Of Life in Parkinson's Patients

Read the detailed description

This study will be conducted to compare the Comparative Effect of Cognitive and Motor Dual Task Training on Balance and Quality Of Life in Parkinson's Patients. total 20 Patients will be recruited according to the inclusion criteria and data will be collected from the Riphah Rehabilitation center Lahore, Muhammadi Medical trust hospital Lahore. Time Up and Go test (TUG) Parkinsons disease Questionnaire 39 (PDQ-39) will be used as data collection tool. To assess the balance and quality of life in parkinson's patients. Patients will be allocated to intervention group by randomization. After approval from ethical committee, data collection will be started and informed consent will be taken from all patients

02

Conditions studied

  • Parkinson Disease
  • Balance; Distorted
  • Postural; Defect

Browse trials for

Keywords

  • Parkinson Disease
  • Balance; Distorted
  • Postural; Defect
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 20 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A stage I-II-III Hoehn and Yahr scale consultant neurologist's diagnosis of Parkinson's disease
  • A stable medication schedule both before and during the trial period
  • can walk without assistive aid

Exclusion criteria

Exclusion Criteria:

  • Other neurological conditions in additions to Parkinson's disease such as CVA, Head injuries, Trauma
  • Any Musculoskeletal condition e.g., total knee replacement surgery and rheumatoid arthritis
  • Sensory impairments (vestibular dysfunctions)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    experimental group

    cognitive training and conventional training

    Other: cognitive training and conventional training

  • Active comparator
    control group

    motor dual task training and conventional training

    Other: motor dual task training along with conventional therapy

Interventions

  • Othercognitive training and conventional training

    cognitive training along with conventional therapy

  • Othermotor dual task training along with conventional therapy

    motor dual task training along with conventional therapy

06

What researchers measure

Primary outcomes

  1. time up and go test

    In time up and go test instruct patient stand up and then walking 3 meters far then rotate and come back. Therapist noted the whole procedure time

    Time frame: 9 months

  2. Parkinson Disease Questionnaire-39 (PDQ-39).

    Parkinson Disease Questionnaire-39 (PDQ-39).The tool carried out 39 items. The tool carried out 39 items. For each domain, five answer shows that every part score is 0 (good) to 100 (critical). Decreased scores showed better quality of life

    Time frame: 9 months

07

Study locations

1 site
  • Riphah International University
    Islamabad, Fedral 44000, Pakistan
08

References and documents

Publications

  • Bordignon A, Devita M, Sergi G, Coin A. "Cerebellar cognitive reserve": a possible further area of investigation. Aging Clin Exp Res. 2021 Oct;33(10):2883-2886. doi: 10.1007/s40520-021-01795-1. Epub 2021 Feb 17. No abstract available. PubMed 33595777 ↗
  • Onder H, Ozyurek O. The impact of distinct cognitive dual-tasks on gait in Parkinson's disease and the associations with the clinical features of Parkinson's disease. Neurol Sci. 2021 Jul;42(7):2775-2783. doi: 10.1007/s10072-020-04874-9. Epub 2020 Nov 4. PubMed 33150515 ↗
  • Bouscary A, Quessada C, Rene F, Spedding M, Turner BJ, Henriques A, Ngo ST, Loeffler JP. Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Semin Cell Dev Biol. 2021 Apr;112:82-91. doi: 10.1016/j.semcdb.2020.10.008. Epub 2020 Nov 5. PubMed 33160824 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05506813
Lead sponsor
Riphah International University
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Jan 1, 2022
Primary completion
Aug 20, 2022
Completion
Aug 20, 2022
Last update
Nov 9, 2022

Study contacts

Zeest Hashmi, MSNMPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion